Birinapant improves imiquimod-induced psoriasis in BALB/c mice

This study investigates the effects of birinapant, a novel compound, on psoriasis-like symptoms induced by imiquimod in Balb/c mice.

Male Balb/c mice were treated with imiquimod (IMQ) to induce psoriasis-like symptoms. The clinical characteristics of psoriasis were assessed using the Psoriasis Area and Severity Index, as well as back skin thickness, skin length and mass, and body weight alterations. The treatment groups included those receiving birinapant, with the assessment on the levels of interleukin-17 and tumor necrosis factor -α, two key cytokines involved in the inflammatory process of psoriasis. The study found that birinapant significantly reduced the levels of these cytokines, providing reassurance about its potential to combat psoriasis. Additionally, the study evaluated the effect of birinapant on oxidative stress levels to determine its role in maintaining skin homeostasis.

The findings from this study revealed that mice subjected to IMQ-induced psoriasis exhibited positive responses to 21 days of treatment with birinapant (50 mg/kg). The levels of interleukin-17 and tumor necrosis factor-alpha, in the skin of IMQ-treated mice significantly decreased, indicating its effectiveness in reducing inflammation associated with psoriasis. Furthermore, Birinapant positively affected oxidative stress maintenance, suggesting its potential role in promoting skin health and homeostasis.

By demonstrating birinapant's efficacy, this research paves the way for further studies that could lead to the development of more effective therapies for psoriasis.